Analysts Offer Insights on Healthcare Companies: Agilent (A), Henry Schein (HSIC) and Biogen (BIIB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Agilent (A – Research Report), Henry Schein (HSIC – Research Report) and Biogen (BIIB – Research Report).

Agilent (A)

Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on Agilent today and set a price target of $135.00. The company’s shares closed last Monday at $113.98.

According to TipRanks.com, Arias is ranked 0 out of 5 stars with an average return of -9.5% and a 39.3% success rate. Arias covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Exact Sciences, and Mettler-Toledo.

Agilent has an analyst consensus of Moderate Buy, with a price target consensus of $129.83.

See Insiders’ Hot Stocks on TipRanks >>

Henry Schein (HSIC)

Piper Sandler analyst Jason Bednar maintained a Buy rating on Henry Schein today and set a price target of $78.00. The company’s shares closed last Monday at $68.61.

According to TipRanks.com, Bednar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.4% and a 33.7% success rate. Bednar covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Alpha Tau Medical Ltd, and Merit Medical Systems.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Henry Schein with a $75.00 average price target, representing an 8.9% upside. In a report issued on November 9, Stifel Nicolaus also upgraded the stock to Buy with a $70.00 price target.

Biogen (BIIB)

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Biogen today and set a price target of $350.00. The company’s shares closed last Monday at $230.11, close to its 52-week low of $220.86.

According to TipRanks.com, Raymond is a 3-star analyst with an average return of 0.9% and a 46.7% success rate. Raymond covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Deciphera Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biogen with a $315.70 average price target, a 38.4% upside from current levels. In a report issued on November 7, Wells Fargo also maintained a Buy rating on the stock with a $343.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on A:

• Agilent (NYSE:A) Jumps on Impressive Q4 Results
• Agilent options imply 5.2% move in share price post-earnings
• Options Volatility and Implied Earnings Moves Today, November 20, 2023
• Options Volatility and Implied Earnings Moves This Week, November 20 – November 23, 2023
• A Earnings Report this Week: Is It a Buy, Ahead of Earnings?